Pharmacokinetic analysis of carboplatin dosing suggests a more accurate prediction of toxicity when the dose is based on the area under the plasma concentration vs time curve (AUC) instead of body surface area (BSA). We retrospectively calculated the carboplatin AUC of 117 patients who received an autologous stem cell transplant following a conditioning regimen consisting of carboplatin 1800 mg/m 2 and cyclophosphamide 6000 mg/m 2 to identify whether higher carboplatin exposure resulted in an increase in regimen-related non-hematologic toxicities. The most common non-hematologic toxicities were gastrointestinal and hepatic. Twenty (17%) patients experienced additional уgrade 2 toxicity, specifically, renal toxicity significantly associated with a higher median AUC of 10.2 mg/ml ؊1 min (P = 0.001). Prior platinum therapy was also significantly associated with toxicity (P = 0.052). While carboplatin dose based on BSA varied minimally (median 990 (range 450-1340) mg, the calculated AUC showed a near four-fold range of exposure (median 7.8 (range 3.6 to 13.8) mg/ml ؊1 min). These data suggest a relationship between nonhematologic adverse events and the estimated AUC. Prospective trials will be necessary to identify the target carboplatin AUC which optimizes outcome and minimizes toxicity in the autologous transplant setting.
dent ototoxicity, hepatotoxicity and severe renal dysfunction can complicate high-dose regimens. 6, [9] [10] [11] The relatively simple pharmacokinetics of carboplatin suggest that drug exposure measured by the area under the plasma concentration vs time curve (AUC) correlates closely with renal function, 8, [12] [13] [14] and that toxicities may be more accurately predicted when the dose is determined not on the patient's body surface area (BSA), but by achieving a specific carboplatin AUC. 5, 8, 15, 16 A dosing equation based on pre-treatment renal function as assessed by glomerular filtration rate (GFR) has been designed by Calvert and colleagues13 where the carboplatin dose (mg) = AUC (mg/ml Ϫ1 min) ϫ (GFR (ml/min) + 25). Twenty-five is the estimated non-renal losses of carboplatin in adults. Evaluated in both retrospective and prospective studies, this formula has become a reliable tool to calculate the optimal dose for conventional single agent as well as high-dose carboplatin therapy. 5, [17] [18] [19] [20] While other models for carboplatin dosing have been derived, 21, 22 Calvert's equation offers a simple and easy bedside method for dosing.
Based on hematologic toxicity reported with single agent carboplatin, and combination regimens using conventional dosing carboplatin with other alkylating agents, an AUC of between 5 to 7 mg/ml Ϫ1 min is generally recommended. 5, 13, [23] [24] [25] While these conventional dosing schemas are considerably different from high-dose therapy utilized in transplant conditioning regimens, specific target AUCs for high-dose carboplatin have not been welldefined.
There has been considerable experience with the combination of high-dose cyclophosphamide and carboplatin with autologous BMT and PBSCT. 6, 10 Toxicities other than myelosuppression may be associated with a higher drug exposure.
In an earlier phase I/II dose escalation study of high-dose carboplatin and cyclophosphamide, 43 patients with solid tumors were treated. 10 The maximally tolerated dose (MTD) of carboplatin was 1800 mg/m 2 when given in combination with cyclophosphamide 6000 mg/m 2 . Demonstrated anti-tumor effects with minimal toxicity led to an expanded cohort of 117 patients treated at the MTD. Since the GFR and thus the clearance of carboplatin may have differed between patients, irrespective of the body surface area, some patients in this trial may have achieved a higher systemic exposure than others. Thus, we retrospectively calculated the carboplatin AUC of 117 patients treated with this combination regimen in order to identify whether increased non-hematologic toxicities were associated with higher carboplatin exposure.
Patients and methods

Study design
The toxicity profiles of 117 consecutively treated autologous transplant patients with chemosensitive solid tumors were analyzed. Eligibility for transplantation included acceptable cardiac (left ventricular ejection fraction у45%), renal (serum creatinine р1.5 mg/dl or creatinine clearance у60 ml/min), and liver (serum bilirubin р2 or transaminase р2 ϫ normal) function and an ECOG performance status of 0 or 1. The conditioning regimen consisted of fixed dosing cyclophosphamide 2000 mg/m 2 daily and carboplatin 600 mg/m 2 daily given on 3 consecutive days (transplant days −5, −4, −3) followed by infusion of autologous peripheral blood stem cells (PBSC) on transplant day 0. Both cyclophosphamide and carboplatin were dosed using BSA according to actual or ideal body weight, whichever was less. All patients were treated at the Massachusetts General Hospital according to an Investigational Review Board approved protocol.
Patient data included demographics, prior therapy, prospectively recorded toxicity grading, and other transplantrelated complications. Data on all 117 patients were available for all analyses.
Determination of carboplatin AUC
The Cockcroft and Gaulf formula 26 was used to derive creatinine clearance (CC) for each adult patient using age, weight in kg, and the serum creatinine with a 15% reduction for female patients. For pediatric patients CC was normalized to BSA (ml/min/1.73 m 3 ). 27 The serum creatinine was determined daily prior to the infusion of carboplatin. The AUC was then calculated for each dose of carboplatin by rearranging the Calvert formula such that the AUC = dose/(GFR + 25). The GFR and dose used in the formula are unnormalized. Complete blood counts, electrolytes and liver function tests were determined daily prior to each dose of carboplatin and an EKG was performed prior to each dose of cyclophosphamide.
Supportive care
All patients were treated in high efficiency particulate air (HEPA)-filtered rooms and received antimicrobial prophylaxis. Broad-spectrum antibiotic therapy was initiated for temperature greater than 38°C. Irradiated leukofiltered packed RBCs and platelets were transfused to maintain a hematocrit greater than 25% and a platelet count greater than 20 ϫ 10 9 /l.
Toxicity
Patients were prospectively graded for toxicities on a daily basis using the Seattle Toxicity Grading System. 28 Institutional BMT data forms were used to monitor and record organ toxicities of the skin, mucosa, bladder, liver, kidney, lung, heart, gastrointestinal tract and central and peripheral nervous system.
Statistical analysis
The primary analysis was performed to determine the difference between the distribution of the calculated carboplatin AUC for patients who developed уgrade 2 toxicities and those who did not. The comparison was evaluated nonparametrically by the Wilcoxon rank sum test. The distribution of carboplatin dose was similarly analyzed between the toxicity subgroups. Fisher's exact test was used to compare the incidence of уgrade 2 toxicity between the two patient groups defined by prior platinum therapy and also by a specified threshold of calculated AUC. All reported P-values are based on two-sided hypothesis tests.
Results
The base-line characteristics of the 117 patients who were enrolled on this protocol and received an autologous PBSCT between February 1994 and 1999 are shown in Table 1 . Female patients undergoing autologous transplantation for metastatic breast cancer constituted the majority of enrolled subjects. The median age was 43 (range 5-63) years. Three pediatric patients were enrolled on this study (ages 5, 12 and 16 years) and were included in all the analyses. Sixty-one patients (52%) had received two or more chemotherapy regimens. Thirty patients (26%) received radiation therapy and 31 patients (26%) had received platinum therapy (cisplatin or carboplatin) prior to their transplant. All patients received their full intended transplant conditioning regimen and peripheral blood stem cells as hematologic rescue except one patient who was given both peripheral blood and bone marrow stem cell support. Carboplatin dose was correctly calculated based on BSA using ideal or actual body weight, whichever was less as specified by the protocol in 108 (92%) of the 117 patients. The median carboplatin dose for patients with or without a уgrade 2 non-hematologic toxicity was 990 (852-1330) mg and 990 (450-1340) mg, respectively (Table 2) . Nine patients were dosed incorrectly using the higher of the two weights. No significant relationship was found between the mg/m 2 dosing (ideal or actual) and the occurrence of уgrade 2 toxicity.
The median serum creatinine, estimated GFR and calculated AUC for each dose of carboplatin was calculated. No significant difference was seen between each succeeding day of treatment; thus only the pre-treatment (day −5) data were used for the analyses ( Table 2 ). The median estimated GFR for all patients was 102 (range 43-259) ml/min. There was no difference between males and females. However, there were four female and six male patients with an estimated GFR Ͼ140 ml/min. While the day −5 median calculated AUC for the population was 7.8 mg/ml Ϫ1 min the range was broad (3.6 to 13.8 mg/ml Ϫ1 min). The cumulative median AUC for the 3 dosing days was 24.0 (range 11.6-40.8) mg/ml Ϫ1 min. Prior therapy with either a cisplatin-or carboplatin-containing regimen was found to have a significant impact on the occurrence of уgrade 2 non-hematologic toxicity. While no difference in the median serum creatinine or calculated AUC was found in the 31 patients who received prior platinum therapy, nine (29%) developed a уgrade 2 non-hematologic toxicity (excluding hepatic and GI toxicity). This is compared to 11 (13%) of 86 patients without prior platinum therapy who developed a уgrade 2 nonhematologic toxicity (P = 0.052).
The calculated AUC of carboplatin had no effect on the time to neutrophil engraftment (ANC Ͼ500/l) or platelet recovery (20 000/l). One hundred and sixteen evaluable patients (one patient died prior to engraftment) successfully achieved an absolute neutrophil count of у0.5 ϫ 10 9 /l at Table 2 Carboplatin dosing and calculated AUC (n = 117) 
Non-hematologic toxicity
Greater than or equal to grade 2 non-hematologic toxicity was reported in 73 (62%) patients. The median AUC for patients who developed any уgrade 2 toxicity was 7.8 (3.6-13.8) mg/ml Ϫ1 min compared to 7.8 (4.5-11.4) mg/ml Ϫ1 min for patients who did not develop уgrade 2 toxicity.
The most common grade 2 non-hematologic toxicities in this population were gastrointestinal (GI) toxicity (nausea/vomiting) in 48 (41%) patients and hepatotoxicity in 41 (35%) patients as evidenced by a rise in hepatic transaminase levels ( Table 3) . None of the patients experienced Ͼgrade 2 GI or hepatic toxicity. The calculated carboplatin AUC for patients who did or did not develop grade 2 GI or hepatic toxicity was not significantly different.
Non-hematologic toxicity (excluding hepatic and GI toxicity)
Toxicity (уgrade 2) involving other organ systems are listed in Table 4 for each of the 20 (17%) patients who experienced 25 toxic events. Nineteen of the 20 patients had an AUC у7.0 mg/ml Ϫ1 min and the median calculated AUC and carboplatin dose for all 20 patients was 8.7 (range 6.0-13.8) mg/ml Ϫ1 min and 995 (range 864-1200) mg, respectively. One instance of transplant-related mortality (TRM) occurred. A 63-year-old patient (patient No. 18) developed a grade 4 cardiac toxicity presenting on transplant day −1 with new EKG changes (low voltage) and a pericardial friction rub. The patient developed severe myopericarditis and tamponade leading to multi-organ failure and asystolic cardiac arrest on day +1 post transplant. The calculated AUC of this patient was 12.4 mg/ml Ϫ1 min, which was substantially higher than the calculated median AUC of the entire cohort. The development of уgrade 2 renal toxicity was significantly associated with the calculated AUC. The median AUC for the eight patients was 10.2 (range 8.0-13.8) mg/ml Ϫ1 min (P = 0.001) ( Table 3 ). Eight (7%) patients had a rising serum creatinine beginning on day +1, to a median maximum of 3.5 (range 1.6-4.4) mg/dl. In all but one case (patient 18), the toxicity was reversible with minimal intervention (diuretics and hydration).
Four patients developed уgrade 2 cardiotoxicity. Rapid atrial fibrillation occurred in two patients on transplant day −2 which was reversible with the initiation of antiarrhythmic medication. In one patient the EKG showed low voltage and mild ST elevations on transplant day −2. By day 15, the patient underwent a pericardiocentesis for an increasing pericardial effusion and impending tamponade. The patient responded well to both corticosteroids and nonsteroidal anti-inflammatory therapy and was discharged on day +20. Grade 4 toxicity was seen in only one of the four patients (patient 18). The median AUC in these four patients of 9.0 (range 7.0-12.4) mg/ml Ϫ1 min was not significantly different from the median AUC of the entire cohort.
Greater than or equal to grade 2 pulmonary toxicity occurred in two patients. One patient developed dyspnea and mild pulmonary decompensation following her stem cell infusion with a decrease in oxygen saturation to 89%. Resolution of symptoms occurred following diuretic therapy. The calculated AUC for this patient was 7.9 mg/ml Ϫ1 min. A grade 3 toxicity was seen in another patient (UPN 68), who developed significant inspiratory rales, with decreased O 2 saturation and tachypnea on transplant day 0. His transplant course was further complicated by cardiac and renal toxicity.
Six (5%) patients developed уgrade 2 neurotoxicity, manifested by tinnitus in three patients (including one pediatric patient, aged 12 years) beginning on transplant day −4, which was complicated by significantly decreased hearing in two of the three patients. Acute onset of bilateral hip pain refractory to morphine was reported in one patient beginning on day −2, which resolved by day 0 following dexamethasone therapy. Another patient experienced neuralgia-type pain on the left side of her head beginning on day +17 post transplant occurring primarily after G-CSF administration and was only mildly relieved with amitriptyline and capsaicin. The patient's symptoms had improved at the time of discharge. A grand mal seizure occurred in one patient on day 0, during her stem cell infusion, and was successfully treated with phenytoin without recurrence. The median AUC for these six patients was 7.8 (range 6.0-8.8) mg/ml Ϫ1 min which was not significantly different from the entire cohort.
Gross hematuria and epistaxis were seen in one patient who was refractory to platelet transfusions and one patient developed grade 2 oral mucositis. Three patients developed a macular pruritic rash, which was thought to be a result of antibiotic therapy.
Patients with an AUC of у7.0 (7.0-14.0) mg/ml Ϫ1 min experienced significantly more grade 2 non-hematologic toxicities of other organ systems than patients with a calculated AUC Ͻ7.0 mg/ml Ϫ1 min (P = 0.023), demonstrating a threshold AUC level of 7.0 mg/ml Ϫ1 min for toxicity.
Outcome
Given the heterogeneous groups of diseases, it is difficult to analyze the impact of the calculated AUC on anti-tumor responses. No association was seen, however, between the calculated AUC and achievement of a complete response in patients with measurable tumor. Fifty-four percent of the patients with a calculated AUC below the median AUC of 7.8 mg/ml Ϫ1 min achieved a complete response compared to 56% of the patients who had a calculated AUC above the median.
Discussion
The aim of this study was to determine if the non-hematologic toxicities occurring in autologous PBSCT recipients treated with a high-dose carboplatin and cyclophosphamide conditioning regimen were related to the systemic carboplatin exposure. We retrospectively calculated the AUC of carboplatin using the Calvert formula and found that higher AUCs were associated with occurrence of a уgrade 2 nonhematologic toxicity (excluding hepatic and GI toxicity). This trend was increasingly evident at higher calculated AUCs suggesting a continuous negative effect of higher AUCs and the occurrence of toxic events. Additionally patients who were previously treated with a platinum-containing regimen were significantly more likely to develop уgrade 2 non-hematologic toxicity. Non-hematologic toxicities in this study were similar to those seen in an earlier phase I/II dose escalation study, by Spitzer et al, 10 where the primary adverse events were GI and transient chemotherapy-induced hepatitis. In the six patients treated at the MTD, no renal toxicity was observed. In our analysis, however, уgrade 2 renal toxicity was significantly associated with the carboplatin AUC and was a frequent adverse event observed exclusively in patients with a calculated AUC of у8.0 mg/ml Ϫ1 min. Consequently, limiting fixed weight-based dosing regimens to a ceiling carboplatin AUC (р7 mg/ml Ϫ1 min/dose) may prove to be helpful in preventing this toxicity.
Clinically significant hearing loss is uncommon with conventional carboplatin dosing. However, the use of higher doses or combination therapy with other potentially ototoxic drugs, such as cyclophosphamide, warrants caution. 11 In a study by van Warmerdam et al, 9 31 patients were treated with high-dose carboplatin 400 mg/m 2 daily, cyclophosphamide1200 mg/m 2 daily and thiotepa 120 mg/m 2 daily followed by PBSCT as part of a single, double or triple transplant program. A cumulative carboplatin AUC of Ͼ30 mg/ml Ϫ1 min following multiple transplant courses was found to be predictive for the development of clinically significant ototoxicity, especially in patients who had prior cisplatin-containing chemotherapy. A lower cumulative systemic drug exposure (median cumulative AUC: 24.0 (range 10.8-41.4) mg/ml Ϫ1 min) in our study may explain the low incidence of auditory toxicity.
A fatal cardiomyopathy, associated with grade 3 renal and pulmonary toxicity developed in one patient with a calculated carboplatin AUC of 12.4 mg/ml Ϫ1 min. While a high carboplatin exposure may have contributed to his demise, the well-recognized cyclophosphamide-induced cardiomyopathy 26, 27 was believed to be the primary etiology of his cardiac toxicity. The impact of combination therapy with cyclophosphamide on the observed toxicities in this study must accordingly be considered.
The Calvert formula was designed to accurately predict the carboplatin AUC based on renal function and has demonstrated good correlation with the measured plasma carboplatin AUC in some, 17, 14 but not in all studies. 29 31 are not always available in transplant centers. Alternatively, a 24-h urinary CC may provide a reasonable estimate of GFR. However, it requires time and patient compliance. The Cockcroft and Gault formula using serum creatinine is the easiest and most convenient way to estimate the GFR and has become an accepted and useful measure in clinical practice. 5, 32 Correlation between the Cockcroft and Gault formula and the Cr 51 EDTA method for estimating the GFR has varied depending on the study. 29, [32] [33] [34] An evaluation of 10 patients treated at this institution with a similar transplant regimen for ovarian cancer, revealed a very close approximation of the pretransplant GFR, estimated by both the Cockcroft and Gault formula, and by a 24-h urine collection. Due to the retrospective nature of this study, we were unable to compare our calculated carboplatin AUC with that of a measured AUC to determine the accuracy and precision of the Calvert formula, using the Cockcroft and Gault GFR estimate.
In our study, the estimated GFR measured daily prior to carboplatin dosing showed no significant day to day variation. Although all patients at baseline had normal renal function, the estimated GFR showed a wide interpatient variability and this was reflected in the near four-fold range of the calculated AUC. This variability in the estimated GFR is similar to that reported by other investigators. 5 Moreover, while the calculated AUC varied widely, the administered milligram dose of carboplatin did not. Thus, a considerable range of drug exposures occurred in this group of patients who were thought to be uniformly conditioned, potentially affecting therapeutic efficacy, as well as toxicity risk.
Our data, in which calculated AUCs greater than 7 mg/ml Ϫ1 min were associated with significantly more regimen-related toxicities, suggest that pharmacokinetic dosing of carboplatin for autologous stem cell transplant conditioning therapy may be useful to minimize toxicity. We are currently recommending a ceiling AUC of 7 to 8 mg/ml Ϫ1 min for our carboplatin-conditioning regimens. Prospective high-dose combination chemotherapy studies will be necessary, however, to identify target carboplatin AUCs which optimize outcome and minimize toxicity in the autologous transplant setting.
